

# NEWSLETTER March – April 2020

## CEO's greetings

The world has changed dramatically over the past two months due to Covid-19. It feels almost unfair how little impact the pandemic has had on Herantis. Our clinical studies are fully recruited; almost all patient treatments completed; and our team's hard work and planning is ensuring minimal impact on the remaining procedures, as explained [in our webcast](#).

However, at Herantis and throughout the world, people are in an exceptional isolation from friends and family. My Swedish friends joke that the stereotypic, introvert Finns shouldn't even notice any change... but jokes aside: Let's keep in touch with friends and colleagues, and remain sensitive to any signals of worsening stress. That would not be unexpected under the circumstances.

At Herantis, we keep in touch e.g. with daily virtual coffee breaks over videoconference. It's reassuring to actually see colleagues (and, sometimes, their kids and pets!) smiling, laughing and reminding that we'll get through this together.

## CLINICAL STUDIES

- **Breast Cancer Associated Lymphedema:** Phase 2 study AdeLE is fully recruited. Results are expected in Q1/21 after a 12-month blinded follow-up. See [Lymfactin website](#) for details.
- **Parkinson's disease:** Phase 1-2 study with CDNF is fully recruited. Based on 6-month results CDNF is safe with encouraging biological signals of neurorestoration in some patients. 12-month results are expected in Q3/20.
- **Breast Cancer Associated Lymphedema:** Phase 1 study is in long-term follow-up. Based on 12-month follow-up, Lymfactin® is safe and well tolerated.

Keep up-to-date on Herantis:



Contact us



@Herantis Pharma



Subscribe

## PLANNED ACTIVITIES

- Note that investor events are currently significantly reduced due to Covid-19. Herantis intends to continue webcasts and virtual events instead.
- **ABGSC Life Science Summit\***, 26 May 2020 in Stockholm: Company presentation to Swedish investors
- **Half-year report**, 27 Aug 2020
- **12-month data from Phase 1-2 clinical study with CDNF in Parkinson's disease**, Q3/2020.
- **Pareto Healthcare Conference\***, 3 Sep 2020 in Stockholm: Company presentation to Swedish investors
- **Topline data of Phase 2 clinical study with Lymfactin® in Breast Cancer Associated Lymphedema**, Q1/2021

\*Subject to Covid-19 situation

## Herantis of the month



The new normal: Virtual morning coffee with the team

## Highlights from team

Warm welcome to our new Board member Mats Thorén! Those of us who have only seen you on screen are really looking forward to meeting you face to face, as soon as the travel restrictions allow. Congrats also to our newly elected and very experienced Chairman Timo Veromaa!

Our team is also innovative on how to stay fit through the pandemic. Virtual workout classes, setting up a home gym corner, orienteering, biking, long-distance running... a healthy life is possible despite Covid-19.

## Topics of interest

Edison Investment Research revised their analysis on Herantis after reviewing our first Parkinson's results. Their new interim report is now available: [Herantis Pharma – Funded to key data inflection points](#)

Herantis' Annual General Meeting was truly unique under the Covid-19 restrictions. Our warmest thanks to our shareholders who respected the situation and stayed home and followed the meeting via webcast ([recording available](#)).

## Herantis in the news

Neurocenter Finland covered Herantis' Parkinson's program in their article [Potential breakthrough in the treatment of Parkinson's disease](#).

Nyhetsbyrån Direkt interviewed Herantis' CEO on Q4/19 in a [video interview](#).

Herantis held a virtual Capital Markets Day in March because physical events are not possible. While this is not exactly news on Herantis we have made the [webcast available](#) for anyone interested.